In contrast to intestinal P-gp inhibition, which is seldom the cause of clinically significant DDIs, induction of P-gp has been demonstrated to decrease the bioavailability of P-gp substrates, leading to clinically significant DDI . All the designed compounds have shown a good balance between P-gp inhibition and substrate tendencies which may lead to less DDIs and toxicity.